Evidence map›Paper›PMID 29862060›Full record

ArticleBehavioral sciences (Basel, Switzerland)2018

Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease.

Ivonne Pedroso, Marité Garcia, Enrique Casabona, Lilia Morales, Maria Luisa Bringas, Leslie Pérez, Teresita Rodríguez, Ileana Sosa, Yordanka Ricardo, Arnoldo Padrón and 1 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Behavioral sciences (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01010802 phase1completednot on this map

Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)

TypeinterventionalSponsorInternational Center for Neurological Restoration, CubaRan2008 to 2009Enrolled10ConditionsParkinson DiseaseArmsErythropoietin human recombinant (EPOrh)
NCT04110678 phase1 / phase2completednot on this map

Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial

TypeinterventionalSponsorInternational Center for Neurological Restoration, CubaRan2015 to 2017Enrolled26ConditionsParkinson DiseaseArmsNeuroEPO
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ivonne PedrosoInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).
Marité GarciaInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).
Enrique CasabonaInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).
Lilia MoralesInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).ORCID https://orcid.org/0000-0003-0205-0733
Maria Luisa BringasThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID https://orcid.org/0000-0003-2507-1959
Leslie PérezCenter of Molecular Immunology, La Habana 11300, Cuba; leslie@cim.sld.cu (L.P.); teresita@cim.sld.cu (T.R.); daniel@cim.sld.cu (D.A.).
Teresita RodríguezCenter of Molecular Immunology, La Habana 11300, Cuba; leslie@cim.sld.cu (L.P.); teresita@cim.sld.cu (T.R.); daniel@cim.sld.cu (D.A.).
Ileana SosaNational Center for the Production of Laboratory Animal Breeding, La Habana 10800, Cuba; Iliana.sosa@cenpalab.cu.
Yordanka RicardoInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).
Arnoldo PadrónInternational Center for Neurological Restoration, La Habana 11300, Cuba; merlincuba@nauta.cu (M.G.); enrique@neuro.ciren.cu (E.C.); lily@neuro.ciren.cu (L.M.); yordanka@neuro.ciren.cu (Y.R.); padron@neuro.ciren.cu (A.P.).
Daniel AmaroCenter of Molecular Immunology, La Habana 11300, Cuba; leslie@cim.sld.cu (L.P.); teresita@cim.sld.cu (T.R.); daniel@cim.sld.cu (D.A.).ORCID https://orcid.org/0000-0003-2507-1959
International Center of Neurologic Restoration · CUCenter of Molecular Immunology (Cuba) · CUUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cognitiveneuroprotectionParkinson

Identifiers

PMID29862060
PMCPMC5981245
OpenAlexW2803255453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.